Top Markets
Coin of the day
TME Pharma N.V. TME Pharma N.V.

TME Pharma N.V.

ALTME
Κατάταξη σε μετοχές #33659
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Τιμή μετοχής
$0.07591393
Τελευταίος συγχρονισμός: 2026-08-14
Κεφαλαιοποίηση
$7.15M
Αλλαγή (1 ημέρα)
3.90%
Αλλαγή (1 έτος)
-41.05%
Χώρα
DE
Εμπόριο TME Pharma N.V. (ALTME)

Κατηγορία

Ιστορικό τιμής μετοχής για την TME Pharma N.V. (ALTME)
Υψηλότερη τιμή κλεισίματος: $0.07 στις 2026-08-01

Χαμηλότερη τιμή κλεισίματος: $2.42K στις 2016-09-01
Ιστορικό τιμής μετοχής της TME Pharma N.V. από 2016 έως 2026
Ετήσια απόδοση τιμής μετοχής
Έτος Απόδοση
2026 (TTM) 32.43%
2025 -15.09%
2024 -67.73%
2023 -81.54%
2022 -95.65%
2021 -45.73%
2020 27.62%
2019 -67.02%
2018 -81.06%
2017 -65.91%
2016 0.00%
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Τιμή μετοχής Μεταβολή 1Έτ% Χώρα
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE